A phase 2, open-label, single-arm, multicenter, multinational study to evaluate the antitumor activity and safety of IPI-504 [retaspimycin], a novel small molecule inhibitor of heat shock protein 90(HSP90), in patients with locally advanced or metastatic human epidermal growth factor receptor 2 positive(HER2+) breast cancer that has progressed despite prior Her2-targeted therapy.

Trial Profile

A phase 2, open-label, single-arm, multicenter, multinational study to evaluate the antitumor activity and safety of IPI-504 [retaspimycin], a novel small molecule inhibitor of heat shock protein 90(HSP90), in patients with locally advanced or metastatic human epidermal growth factor receptor 2 positive(HER2+) breast cancer that has progressed despite prior Her2-targeted therapy.

Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 05 Feb 2010

At a glance

  • Drugs Retaspimycin (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors MedImmune
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 05 Feb 2010 Trial phase changed from II to I/II as reported by ClinicalTrials.gov.
    • 05 Feb 2010 Last checked against ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top